FDA launches new rare disease review framework
October 17, 2026
Important Health - What Actually Matters
Health Policy
Tech giants’ R&D spending nears pharma giants’ total
October 19, 2026
Tech R&D spending hit $118.5 billion in 2025, just under the $123.7 billion total of the ten largest drugmakers, showing...
READ THE ARTICLE 
PharmSci conference adds new research tracks
October 16, 2026
Talus Bio Skips Protein Folding for 5,000-Fold Drug Speed
October 14, 2026
RISK FACTORS
Cancer vaccine uses COVID immune memory
Celloram develops cancer vaccine using COVID immune memory to activate T cells against tumors in mice.
Apixaban Cuts Stroke Risk in Kidney Patients
Apixaban may cut stroke risk in kidney patients with atrial fibrillation and chronic kidney disease.
Peptides face metabolic stability challenges in treating diseases like obesity and cardiovascular disorders with peptide therapeutics.
Glenmark Pharmaceuticals has introduced Telma AM Biso , a fixed-dose combination tablet containing telmisartan, amlodipine, and bisoprolol for...
Health data utilities (HDUs) are becoming essential infrastructure for public health, education, and rural care coordination at Civitas...
UNC researchers test doulas and alerts to improve Black maternal health outcomes in a major $10 million study...
All Post
Tech giants’ R&D spending nears pharma giants’ total
Tech R&D spending hit $118.5 billion in 2025, just under the $123.7 billion total of the ten largest drugmakers, showing...
FDA launches new rare disease review framework
FDA's rare disease framework, unveiled on Oct. 14, offers a review process to standardize expectations and cut uncertainty for sponsors...
PharmSci conference adds new research tracks
AAPS launches new research tracks at PharmSci 360, exploring scientific research integrity in AI era and emerging drug development technologies.
Sheba Medical Center Partners with OpenAI to Advance AI-Powered Healthcare
Sheba Medical Center partners with OpenAI to advance AI-powered healthcare, integrating ChatGPT for clinicians across its network.
Talus Bio Skips Protein Folding for 5,000-Fold Drug Speed
Drug discovery speed improves 5,000-fold as Talus Bio skips protein folding to target previously undruggable proteins in their innovative screening...
Expanded Pharma Tariffs Target Smaller Drugmakers Over R&D Fears
Expanded pharma tariffs now target mid-sized and smaller drugmakers, raising R&D costs and industry concerns over innovation and pricing strategies.
FDA finalizes guidance on written responses and meeting types
The FDA has finalized its guidance on written responses and meeting types, revising circumstances for INTERACT meetings under the Prescription...
AbbVie Reports High Cure Rate for Acute Hepatitis C
AbbVie's Maviret achieved a 96% cure rate in a Phase 3 trial for acute hepatitis C, leading to U.S. approval...
AI agents help manage data surge in trials
Phase-3 clinical trials are generating unprecedented data volumes, a trend that fuels the vision of an autonomous clinical trial while...
Peptides face metabolic stability challenges
Peptides face metabolic stability challenges in treating diseases like obesity and cardiovascular disorders with peptide therapeutics.